Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01647828 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
A Phase 1 study, sponsored by OncoMed Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 217
- Enrollment target
NCT01647828 is a Phase 1 study that has completed, run by OncoMed Pharmaceuticals. The registered enrollment target is 217 participants.
The verdict
NCT01647828, a Phase 1 study, has completed, sponsored by OncoMed Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 217 participants
- Enrollment target
Study Summary
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 in combination with nab-paclitaxel and gemcitabine followed by a Phase 2, multicenter, randomized, placebo-controlled portion to evaluate the efficacy and safety of OMP-59R5 in combination with nab-paclitaxel and gemcitabine in subjects with previously untreated stage IV pancreatic cancer.
Interventions
- DRUG Placebo
- DRUG Nab-Paclitaxel
- DRUG Gemcitabine
- DRUG OMP-59R5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01647828
The ClinicalTrials.gov registry entry for NCT01647828 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoMed Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01647828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01647828 about?
NCT01647828 is a clinical study titled "A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer". The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 in combination with nab-paclitaxel and gemcitabine followed by a Phase 2, multicenter, randomized, placebo-controlled portion to evaluate the efficacy and safety of OMP-59R5 in combination with ...
What is the current status of trial NCT01647828?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 217 participants. The study started on 2012-10. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01647828?
The interventions under investigation include: Placebo (DRUG), Nab-Paclitaxel (DRUG), Gemcitabine (DRUG), OMP-59R5 (DRUG).
Who is sponsoring clinical trial NCT01647828?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.